CARM Description — Carisma Therapeutics Inc
Sesen Bio is a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer. Co.'s main product candidate Vicinium (VB4-845), is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive carcinoma in situ of the bladder in patients previously treated with adequate or less than adequate bacillus Calmette-Guerin. Co.'s lead systemically-administered product candidate, VB6-845d, is being developed as a treatment for multiple types of EpCAM-positive solid tumors.
|
|
Free CARM Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Strong Buy (4.00 out of 4) 96th percentile
(ranked higher than approx. 96% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|